Güney, M.C.Süygün, H.Polat, M.Ayhan, H.Keleş, T.Turinay Ertop, Z.Ş.Bozkurt, E.2025-01-052025-01-05202401010-660X10.3390/medicina601220772-s2.0-85213472623https://doi.org/10.3390/medicina60122077https://hdl.handle.net/20.500.14411/10389Background: Mitral regurgitation (MR) is a common condition observed in patients undergoing transcatheter aortic valve implantation (TAVI) for the treatment of aortic stenosis (AS). However, the impact of TAVI on MR outcomes and the factors predicting MR improvement remains uncertain. Understanding these predictors can enhance patient management and guide clinical decisions. Methods: This retrospective cohort study included 156 patients with moderate to severe MR undergoing TAVI. MR severity was assessed via echocardiography at baseline, as well as 6 months and 1 year after TAVI. Patients were divided into groups based on MR reduction: no improvement or worsening, one-degree improvement, and at least two-degree improvement. Clinical, echocardiographic, and procedural characteristics were evaluated as predictive factors for MR improvement after TAVI. Results: MR reduction occurred in 68% of patients at 6 months and 81% at 1 year. Factors predicting a reduction of two grades or more in MR severity included lower baseline LVEDD (OR = 1.345, 95% CI: 1.112–1.628, p = 0.002) lower baseline LA (OR = 1.121, 95% CI: 1.015–1.237, p = 0.024), lower baseline LVMI (OR = 1.109, 95% CI: 1.020–1.207, p = 0.024), and higher baseline EF levels (OR = 1.701, 95% CI: 1.007–2.871, p = 0.047). No significant association was found between MR reduction at 6 months and one-year mortality. (p = 0.65). Conclusions: Baseline echocardiographic parameters are valuable in predicting MR improvement post-TAVI, with LVMI emerging as a novel predictor. However, MR reduction did not independently predict survival, underscoring the need for further research to optimize patient selection and management strategies in TAVI candidates. © 2024 by the authors.eninfo:eu-repo/semantics/closedAccessMitral Regurgitancy ReductionMortalityTaviArticleQ3Q16012